Primary lung cancer: characterization and survival of 1024 patients treated in a single institution

Hawson, G. A. T.; Zimmerman, P. V.; Ford, Cathy A.; Johnston, Noel; Firouz-Abadi, A.

doi:10.5694/j.1326-5377.1990.tb120915.x

Cited by 20 publications

(10 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The demographics of the patient population are consistent with those reported in other similar studies 9,12 , 13 . Metastatic NSCLC is more common in men, and has a median age of approximately 70 years.…”

Section: Discussionsupporting

confidence: 83%

“…Adenocarcinoma was the most common histological type, consistent with most population‐based studies from the United States of America and other countries. This is different to the previous published experience in Australia, where squamous cell carcinoma predominated 9,13 . Of interest is the substantial number of patients who presented with brain metastases.…”

Section: Discussioncontrasting

confidence: 80%

“…Metastatic NSCLC is more common in men, and has a median age of approximately 70 years. Most patients are symptomatic at diagnosis, with respiratory symptoms being the most common presenting complaint 9,13 . Adenocarcinoma was the most common histological type, consistent with most population‐based studies from the United States of America and other countries.…”

Section: Discussionsupporting

confidence: 77%

“…Most patients are symptomatic at diagnosis, with respiratory symptoms being the most common presenting complaint. 9,13 Adenocarcinoma was the most common histological type, consistent with most population-based studies from the United States of America and other countries. This is different to the previous published experience in Australia, where squamous cell carcinoma predominated.…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Five years managing metastatic non‐small cell lung cancer: experience at a teaching hospital

Wong

Rosenthal

DeBoer

et al. 2004

Internal Medicine Journal

View full text Add to dashboard Cite

The present audit demonstrates some shortfalls in the optimal clinical care of patients with metastatic NSCLC at a large teaching hospital. The main selection criteria of consideration for chemotherapy are age, performance status and presence of symptoms. A subset of patients was not referred to either the Medical Oncology Unit or the Palliative Care Unit and consistency in the choice of chemotherapy was lacking. Survival data and the rate of patients entered onto clinical trials are acceptable; however, further improvements can be made by the institution of multidisciplinary clinics and the education of referring clinicians.

show abstract

Section: Discussionsupporting

confidence: 83%

Section: Discussioncontrasting

confidence: 80%

Section: Discussionsupporting

confidence: 77%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Five years managing metastatic non‐small cell lung cancer: experience at a teaching hospital

Wong

Rosenthal

DeBoer

et al. 2004

Internal Medicine Journal

View full text Add to dashboard Cite

show abstract

“…Skinner et al (1990) also showed no survival difference after a mean follow-up of nearly 2 years, but that study was limited by small numbers (6 with LOH/32 without LOH) and by the analysis of l l p 1 5 loci only. In our study, a true clinical difference may not yet be apparent due to the relatively short follow-up of our surgically resected cases, who would be expected to have a good prognosis, that is, 1 year survival of 90% (Hawson et al, 1990).…”

Section: Discussionmentioning

confidence: 74%

Correlation of loss of heterozygosity at 11 p with tumour progression and survival in non‐small cell lung cancer

Fong¹,

Zimmerman²,

Smith³

1994

Genes Chromosomes & Cancer

Self Cite

View full text Add to dashboard Cite

Loss of heterozygosity (LOH) affecting loci at 11p13 and 11p15 occurs in childhood and adult carcinomas, including non-small cell lung cancer (NSCLC). In NSCLC, the highest reported frequency of LOH was 72% at the 11p13 catalase (CAT) locus. As this locus is centromeric to the Wilms' tumour (WT1) locus, possible involvement of WT1 in the pathogenesis of NSCLC was considered. We thus examined 101 cases of NSCLC for LOH at the WT1 and five other polymorphic loci along 11p. At 11p13, the frequencies of LOH were 20% (9/46) at the FSHB locus, 9% (5/53) at the WT1 locus, and 15% (6/41) at the CAT locus. The shortest region of overlap (SRO) at 11p13 was mapped centromeric to, but excluding, the WT1 locus. Only adenocarcinomas showed LOH in this region. At 11p15, LOH affected 23% (18/77) of informative cases, with the highest frequency of 36% at the insulin (INS) locus. The SRO at 11p15 was mapped telomeric to the RRM1 locus. A third region, at 11p13-15 between WT1 and RRM1, was also affected by LOH. LOH at 11p correlated significantly with advanced T stage and nodal involvement in NSCLC tumours. In the squamous cell carcinoma subtype, LOH along 11p also correlated with nodal involvement. Furthermore, squamous tumours with LOH involving 11p13 loci had significantly worse survival than those without LOH. These data suggest that tumor suppressor gene(s) on 11p affect the progression of NSCLC, particularly squamous cell carcinomas.

show abstract

Serum mucin antigens casa and msa in tumors of the breast, ovary, lung, pancreas, bladder, colon, and prostate. A blind trial with 420 patients

Devine

McGuckin

Ramm

et al. 1993

Cancer

View full text Add to dashboard Cite

Background. The tumor markers CASA (cancer‐associated serum antigen) and MSA (mammary serum antigen) have previously been shown to be useful in the clinical management of ovarian and breast carcinoma, respectively, but have not been assessed in other types of cancer. These assays were compared with carcinoem‐bryonic antigen (CEA) and prostate‐specific antigen (PSA) in a blind trial using sera from the Mayo Clinic‐National Cancer Institute (NCI) Diagnostic Serum Bank. Methods. CASA and MSA were assessed retrospectively in a blind trial using 465 serum samples from the Mayo Clinic‐NCI Diagnostic Serum Bank representing malignant and benign disease of the breast, ovary, lung, pancreas, bladder, colon, and prostate and age‐matched and gender‐matched healthy control donors. CASA MSA, and PSA levels were determined using commercially available kits, and CEA values and clinical details were later provided by the Mayo Clinic. Results. CASA and MSA showed good reproducibility in 45 duplicate samples. CASA values were significantly elevated in the serum of patients with malignant tumors of the breast (44%), ovary (58%), lung (56%), prostate (48%), and bladder (54%), but not in those with benign conditions of these organs or pancreatic or colon cancer. MSA levels were only elevated significantly in cancers of the breast (52%) and ovary (58%). CASA showed significantly better sensitivity than either CEA (20%) or MSA (25%) in the detection of lung cancer, whereas CEA showed significantly superior detection of colon cancers (78%). CASA was not as sensitive as PSA in prostate cancer (48% versus 96%), but gave superior specificity in nonmalignant conditions of the prostate (93% versus 70%), although this was not statistically significant. Conclusions. The commercial CASA and MSA assays are reliable and reproducible tests for these tumor markers. In addition to ovarian cancer, CASA is also elevated significantly in many patients with breast, lung, prostate, and bladder cancer and has potential clinical use in patients with these tumors. The use of the MSA assay appears restricted to breast cancer.

show abstract

Primary lung cancer: characterization and survival of 1024 patients treated in a single institution

Cited by 20 publications

References 19 publications

Five years managing metastatic non‐small cell lung cancer: experience at a teaching hospital

Five years managing metastatic non‐small cell lung cancer: experience at a teaching hospital

Correlation of loss of heterozygosity at 11 p with tumour progression and survival in non‐small cell lung cancer

Serum mucin antigens casa and msa in tumors of the breast, ovary, lung, pancreas, bladder, colon, and prostate. A blind trial with 420 patients

Contact Info

Product

Resources

About